Evonile Pharma receives BSE in-principle approval for ₹900 crore rights issue
Novartis India · Pharmaceuticals & Biotechnology
What the filing says
- Board approved issuance of partly paid-up equity shares via rights issue up to ₹9,000 million
- BSE granted in-principle approval for the rights issue on October 30, 2026
- Board and Rights Issue Committee to meet on November 4, 2026 to approve Letter of Offer and finalize issue details
Why it's rated notable: the amount is 22% of market value (20% to 50%)
Original filing
Disclosure Of The Receipt Of In-Principle Approval From The Stock Exchange I.E. BSE Limited In Relation To The Draft Letter Of Offer.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Novartis India
- Fundraise / allotmentNotableEvonile Pharma receives BSE approval for ₹90 crore Rights Issue, board meeting set
- Fundraise / allotmentNotableEvonile Pharma Ltd approves rights issue to raise up to ₹900 crore
- Fundraise / allotmentNotableEvonile Pharma Limited approves ₹90 crore rights issue to raise funds
- Acquisition / mergerNotableNovartis India Limited acquires Minipress trademarks from Pfizer for ₹1250 crore
Other fundraise / allotment filings this fortnight
- Grand Oak Canyons board to consider Rs. 20,67,00,00,000 NCPS allotment on 5 Nov
- Aarti Industries shareholders approve special resolution to raise up to ₹1,000 crore
- Ola Electric approves allotment of 37,02,72,665 partly paid shares in rights issue
- Neogen Chemicals reports Q2 FY27 revenues of ₹296 crore, 42% YoY growth
- Neogen Chemicals Sept-quarter results, ₹600 crore QIP and ₹200 crore NCD redemption plan
- Neogen Chemicals Q2 FY2026-27: QIP completed, standalone profit rises to ₹21.14 crore
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.